Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647816 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00647816 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT00647816, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's propranolol hydrochloride extended-release 160 mg capsules to Wyeth's Inderal LA® 160 mg capsules following a single, oral 160 mg (1 x 160 mg) dose administration under fasting conditions.
Interventions
- DRUG Propranolol Hydrochloride Extended-Release Capsules 160 mg
- DRUG Inderal® LA Capsules 160 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-09 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00647816
The ClinicalTrials.gov registry entry for NCT00647816 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propranolol Hydrochloride Extended-Release Capsules 160 mg is the first listed.
NCT00647816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00647816 about?
NCT00647816 is a clinical study titled "Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg". The objective of this study was to investigate the bioequivalence of Mylan's propranolol hydrochloride extended-release 160 mg capsules to Wyeth's Inderal LA® 160 mg capsules following a single, oral 160 mg (1 x 160 mg) dose administration under fasting conditions.
What is the current status of trial NCT00647816?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2005-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00647816?
The interventions under investigation include: Propranolol Hydrochloride Extended-Release Capsules 160 mg (DRUG), Inderal® LA Capsules 160 mg (DRUG).
Who is sponsoring clinical trial NCT00647816?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.